Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nurix Therapeutics (NRIX) Net Margin (2019 - 2026)

Nurix Therapeutics (NRIX) has disclosed Net Margin for 8 consecutive years, with 1394.34% as the latest value for Q1 2026.

  • Quarterly Net Margin fell 108896.0% to 1394.34% in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 1013.11% through Feb 2026, down 68301.0% year-over-year, with the annual reading at 314.9% for FY2025, 3995.0% up from the prior year.
  • Net Margin for Q1 2026 was 1394.34% at Nurix Therapeutics, down from 1094.77% in the prior quarter.
  • The five-year high for Net Margin was 79.14% in Q2 2023, with the low at 1394.34% in Q1 2026.
  • Average Net Margin over 5 years is 450.84%, with a median of 344.75% recorded in 2023.
  • The sharpest move saw Net Margin soared 41196bps in 2023, then plummeted -108896bps in 2026.
  • Over 5 years, Net Margin stood at 688.74% in 2022, then soared by 60bps to 276.77% in 2023, then fell by -6bps to 292.74% in 2024, then crashed by -274bps to 1094.77% in 2025, then decreased by -27bps to 1394.34% in 2026.
  • According to Business Quant data, Net Margin over the past three periods came in at 1394.34%, 1094.77%, and 289.76% for Q1 2026, Q3 2025, and Q2 2025 respectively.